c-MET Oncogene in Renal Cell Carcinomas

F. Erlmeier; W. Weichert; M. Autenrieth; P. Ivanyi; A. Hartmann; S. Steffens

doi:10.1055/s-0042-115401

c-MET Oncogene in Renal Cell Carcinomas

Translated title of the contribution: c-MET Oncogene in Renal Cell Carcinomas

F. Erlmeier, W. Weichert, M. Autenrieth, P. Ivanyi, A. Hartmann, S. Steffens

Chair of Pathology

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Summary: c-Met plays a significant role in multiple cellular processes. Being encoded by a proto-oncogene, tyrosine kinase supports aggressive tumour behaviour such as tumour invasiveness and formation of metastases. For some subtypes of renal cell carcinoma studies have shown a association between c-Met expression and clinical outcome or prognosis. Therefore, c-Met represents a prognostic marker in renal cell carcinoma. Furthermore, c-MET will play a decisive role as a possible target for targeted therapies in the era of personalised medicine. Especially for RCC, the dual inhibition of VEGF and c-MET tyrosine kinase in cases of metastatic, treatment-resistant tumours is gaining clinical relevance. The role of c-Met has not been fully elucidated for all subtypes of renal cell carcinomas. The relevance of c-Met for the remaining subtypes of renal tumours has yet to be clarified.

Translated title of the contribution	c-MET Oncogene in Renal Cell Carcinomas
Original language	English
Article number	akturo2091425
Pages (from-to)	475-479
Number of pages	5
Journal	Aktuelle Urologie
Volume	47
Issue number	6
DOIs	https://doi.org/10.1055/s-0042-115401
State	Published - 1 Dec 2016

Keywords

HGF
c-Met
prognostic marker
renal cell carcinoma
targeted therapy

Access to Document

10.1055/s-0042-115401

Cite this

@article{064298c5b5b844119830c4f99e668eb8,

title = "c-MET Oncogene in Renal Cell Carcinomas",

abstract = "Summary: c-Met plays a significant role in multiple cellular processes. Being encoded by a proto-oncogene, tyrosine kinase supports aggressive tumour behaviour such as tumour invasiveness and formation of metastases. For some subtypes of renal cell carcinoma studies have shown a association between c-Met expression and clinical outcome or prognosis. Therefore, c-Met represents a prognostic marker in renal cell carcinoma. Furthermore, c-MET will play a decisive role as a possible target for targeted therapies in the era of personalised medicine. Especially for RCC, the dual inhibition of VEGF and c-MET tyrosine kinase in cases of metastatic, treatment-resistant tumours is gaining clinical relevance. The role of c-Met has not been fully elucidated for all subtypes of renal cell carcinomas. The relevance of c-Met for the remaining subtypes of renal tumours has yet to be clarified.",

keywords = "HGF, c-Met, prognostic marker, renal cell carcinoma, targeted therapy",

author = "F. Erlmeier and W. Weichert and M. Autenrieth and P. Ivanyi and A. Hartmann and S. Steffens",

note = "Publisher Copyright: {\textcopyright} Georg Thieme Verlag KGStuttgart · New York.",

year = "2016",

month = dec,

day = "1",

doi = "10.1055/s-0042-115401",

language = "English",

volume = "47",

pages = "475--479",

journal = "Aktuelle Urologie",

issn = "0001-7868",

publisher = "Georg Thieme Verlag",

number = "6",

}

TY - JOUR

T1 - c-MET Oncogene in Renal Cell Carcinomas

AU - Erlmeier, F.

AU - Weichert, W.

AU - Autenrieth, M.

AU - Ivanyi, P.

AU - Hartmann, A.

AU - Steffens, S.

N1 - Publisher Copyright: © Georg Thieme Verlag KGStuttgart · New York.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Summary: c-Met plays a significant role in multiple cellular processes. Being encoded by a proto-oncogene, tyrosine kinase supports aggressive tumour behaviour such as tumour invasiveness and formation of metastases. For some subtypes of renal cell carcinoma studies have shown a association between c-Met expression and clinical outcome or prognosis. Therefore, c-Met represents a prognostic marker in renal cell carcinoma. Furthermore, c-MET will play a decisive role as a possible target for targeted therapies in the era of personalised medicine. Especially for RCC, the dual inhibition of VEGF and c-MET tyrosine kinase in cases of metastatic, treatment-resistant tumours is gaining clinical relevance. The role of c-Met has not been fully elucidated for all subtypes of renal cell carcinomas. The relevance of c-Met for the remaining subtypes of renal tumours has yet to be clarified.

AB - Summary: c-Met plays a significant role in multiple cellular processes. Being encoded by a proto-oncogene, tyrosine kinase supports aggressive tumour behaviour such as tumour invasiveness and formation of metastases. For some subtypes of renal cell carcinoma studies have shown a association between c-Met expression and clinical outcome or prognosis. Therefore, c-Met represents a prognostic marker in renal cell carcinoma. Furthermore, c-MET will play a decisive role as a possible target for targeted therapies in the era of personalised medicine. Especially for RCC, the dual inhibition of VEGF and c-MET tyrosine kinase in cases of metastatic, treatment-resistant tumours is gaining clinical relevance. The role of c-Met has not been fully elucidated for all subtypes of renal cell carcinomas. The relevance of c-Met for the remaining subtypes of renal tumours has yet to be clarified.

KW - HGF

KW - c-Met

KW - prognostic marker

KW - renal cell carcinoma

KW - targeted therapy

UR - https://www.scopus.com/pages/publications/85006857163

U2 - 10.1055/s-0042-115401

DO - 10.1055/s-0042-115401

M3 - Article

C2 - 28006830

AN - SCOPUS:85006857163

SN - 0001-7868

VL - 47

SP - 475

EP - 479

JO - Aktuelle Urologie

JF - Aktuelle Urologie

IS - 6

M1 - akturo2091425

ER -

c-MET Oncogene in Renal Cell Carcinomas

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this